United States Begins Final Phase of Fatty Acids Trade Investigation
Estimated reading time: 2-4 minutes
The United States International Trade Commission (USITC) has announced the scheduling of the final phase of investigations into imports of fatty acids from Indonesia and Malaysia. The investigations, identified as Nos. 701-TA-785-786 and 731-TA-1773-1774, aim to determine if these imports harm the U.S. industry.
The USITC is focusing on whether these fatty acids are sold in the United States at unfair prices. The U.S. Department of Commerce has found preliminary evidence that the imports are subsidized and sold at less-than-fair-value. The fatty acids in question include those listed under specific Harmonized Tariff Schedule of the United States codes.
The investigations started with petitions from Vantage Specialty Chemicals, Inc. in Deerfield, Illinois, submitted on January 28, 2026. The petitions claim that the imports from Indonesia and Malaysia are threatening U.S. industry.
The USITC invites interested parties to participate in the investigation. Those wishing to join must file an entry of appearance at least 21 days before the hearing date.
A hearing will be held on February 4, 2027, at 9:30 a.m. Parties must file requests to appear by January 28, 2027. Prehearing briefs are due by January 28, 2027, and posthearing briefs by February 11, 2027. Parties may submit final comments by March 2, 2027.
The prehearing staff report will be available on January 21, 2027. The Commission emphasizes electronic filings through its Electronic Document Information System (EDIS).
This investigation follows the rules outlined in the Tariff Act of 1930 and the Commission’s Rules of Practice and Procedure.
For further details, contact Stamen Borisson at the USITC or visit their website. The investigations will help determine the impact of imported fatty acids on the U.S. industry and ensure fair trade practices.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
